FDA Update – September/October 2012
News from the FDA on bosutinib (Bosulif), ziv-aflibercept (Zaltrap), and everolimus oral suspension tablets (Afinitor Disperz).
In the News
Aspirin helps in some cancers
Differences in the impact of aspirin in various forms of cancer are highlighted in two studies recently published in the oncology literature.
HF/CM risks in breast chemotherapy
Earlier study findings that anthracycline- or trastuzumab-based treatment for breast cancer raises the risk for heart failure and cardiomyopathy can be extended to a more general population of women.
ACS applauds Supreme Court health care ruling
The ruling preserves vital provisions that are already improving the ability of people with cancer to access needed care.
“Inoperable” pancreatic cancer may be treatable after all
Oncologists at M.D. Anderson Cancer Center found the key to screening for pancreatic cancer lies in the interpretation of preoperative CT scans.
Oncology clinicians work to cope with patient deaths
The grief experienced by the oncologists had unique elements beyond sadness, crying, and sleep loss.
MyCancerCircle creates a community of caregivers
People with cancer and their caregivers can turn to a new Web site to help answer the question from concerned relatives and friends, “What can I do to help?”
FDA Update – July/August 2012
News about pertuzumab injection (Perjeta); ondansetron (Zofran); carfilzomib (Kyprolis); Therascreen KRAS RGQ PCR Kit; Prostate Health Index (phi); and Prepopik
Multidrug approach fights resistance
Research results suggest that of the billions of cancer cells that exist in a patient, only about one in a million is resistant to drugs using targeted therapy.
FDA Update: May/June 2012
Drug Safety Communication on lenalidomide (Revlimid); FDA approval for pazopanib (Votrient)
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in In the News
